Patents by Inventor Komei OKABE
Komei OKABE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230277671Abstract: The present invention provides an improvement in the strength of the scleral by collagen fiber crosslinking via crosslinking treatment of the sclera at the equatorial region of the eye and/or at the posterior pole such as the fundus of the eye. Also provided is the prevention and/or treatment of eye disease by the same. Provided are a photosensitizer used in a crosslinking treatment for the sclera at the equatorial region of the eye and/or at the posterior pole of the eye; a kit containing the same; and a method for emitting light for the crosslinking treatment.Type: ApplicationFiled: July 20, 2021Publication date: September 7, 2023Inventors: Koji OHASHI, Yukie KOYAMA, Yasuhisa TANAKA, Komei OKABE, Toshihiro OGAWA, Mitsuru KAMIKATANO
-
Publication number: 20220126112Abstract: To prove an optical probe that can illuminate an entire desired region at one time, even in a narrow space. An optical probe including: a linear light guide to guide light from a light source device; a planar emitter to be connected to a tip portion of the linear light guide, to emit the light; a reflective surface provided in a part of the planar emitter, to reflect the light having entered the planar emitter; and an emitting surface provided so as to face the reflective surface, to allow the light reflected by the reflective surface to be emitted from a region of the reflective surface.Type: ApplicationFiled: January 23, 2020Publication date: April 28, 2022Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Mitsuru KAMIKATANO, Komei OKABE, Yukie KOYAMA, Koji OHASHI
-
Patent number: 11090296Abstract: The present invention relates to an ophthalmic depot preparation comprising benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide, wherein the volume ratio of benzyl benzoate and/or benzyl alcohol to polyethylene glycol and/or dimethylsulfoxide in the ophthalmic depot preparation is 75:25 to 25:75, and the total amount of benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide contained is 50% (w/w) or more.Type: GrantFiled: March 17, 2016Date of Patent: August 17, 2021Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Komei Okabe, Toyomi Fujisawa, Kazuhito Yamada
-
Publication number: 20200383957Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: ApplicationFiled: May 19, 2020Publication date: December 10, 2020Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
-
Publication number: 20200352852Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: ApplicationFiled: April 27, 2020Publication date: November 12, 2020Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
-
Patent number: 10682340Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: GrantFiled: December 28, 2017Date of Patent: June 16, 2020Assignees: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma Tamraz, Huey-Ching Su, WeiQi Lin, Kazuhito Yamada, Naoki Matsumoto, Sreenivasu Mudumba, Komei Okabe
-
Patent number: 10668011Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: GrantFiled: June 29, 2017Date of Patent: June 2, 2020Assignees: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma Tamraz, Huey-Ching Su, WeiQi Lin, Kazuhito Yamada, Naoki Matsumoto, Sreenivasu Mudumba, Komei Okabe
-
Patent number: 9987368Abstract: Found out is a pharmaceutical composition that sustained-releases a drug for a long term after administration into the body. Provided is a pharmaceutical composition comprising a drug and a polypeptide represented by Ac-(Arg-Ala-Asp-Ala)4-NH2, and further containing an organic solvent selected from the group consisting of polyethylene glycol, dimethyl sulfoxide, glycofurol, and N-methylpyrrolidone.Type: GrantFiled: March 16, 2016Date of Patent: June 5, 2018Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Tatsuya Miyazaki, Kenji Masaki, Komei Okabe, Kazuhito Yamada
-
Publication number: 20180117016Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: ApplicationFiled: December 28, 2017Publication date: May 3, 2018Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
-
Publication number: 20180064818Abstract: Found out is a pharmaceutical composition that sustained-releases a drug for a long term after administration into the body. Provided is a pharmaceutical composition comprising a drug and a polypeptide represented by Ac-(Arg-Ala-Asp-Ala)4-NH2, and further containing an organic solvent selected from the group consisting of polyethylene glycol, dimethyl sulfoxide, glycofurol, and N-methylpyrrolidone.Type: ApplicationFiled: March 16, 2016Publication date: March 8, 2018Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Tatsuya MIYAZAKI, Kenji MASAKI, Komei OKABE, Kazuhito YAMADA
-
Publication number: 20180042907Abstract: The present invention relates to an ophthalmic depot preparation comprising benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide, wherein the volume ratio of benzyl benzoate and/or benzyl alcohol to polyethylene glycol and/or dimethylsulfoxide in the ophthalmic depot preparation is 75:25 to 25:75, and the total amount of benzyl benzoate and/or benzyl alcohol and polyethylene glycol and/or dimethylsulfoxide contained is 50% (w/w) or more.Type: ApplicationFiled: March 17, 2016Publication date: February 15, 2018Applicant: SANTEN PHARMACEUTICAL CO., LTDInventors: Komei OKABE, Toyomi FUJISAWA, Kazuhito YAMADA
-
Publication number: 20180000729Abstract: Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.Type: ApplicationFiled: June 29, 2017Publication date: January 4, 2018Applicants: DURECT CORPORATION, SANTEN PHARMACEUTICAL CO., LTD.Inventors: Wilma TAMRAZ, Huey-Ching SU, WeiQi LIN, Kazuhito YAMADA, Naoki MATSUMOTO, Sreenivasu MUDUMBA, Komei OKABE
-
Patent number: 9579309Abstract: The present invention relates to a prophylactic or therapeutic agent for a posterior ocular disease containing the compound represented by a formula (1), its enantiomer or diastereomer, or their pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: February 27, 2014Date of Patent: February 28, 2017Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Atsushi Yoshida, Sae Akao, Shinji Yoneda, Komei Okabe, Tomomi Kohara
-
Publication number: 20160303240Abstract: The purpose of the present invention is to provide a novel injectable agent having an excellent medicinal agent sustained release property. The injectable agent according to the present invention comprises a medicinal agent, trehalose and gellan gum. It is preferred that the contents of the medicinal agent, trehalose and gellan gum are 0.0001 to 50.00% (w/v), 0.1 to 50.0% (w/v) and 0.01 to 3.00% (w/v), respectively, relative to the total volume of the injectable agent. It is also preferred that the injectable agent can form a depot upon exposure to a phosphate buffer solution or a body fluid (tear fluid, vitreous fluid, etc.).Type: ApplicationFiled: June 23, 2016Publication date: October 20, 2016Inventors: Kenji OKI, Kazuhito YAMADA, Tatsuya MIYAZAKI, Komei OKABE, Sayo HABASHITA, Hiroshi ENOMOTO, Kenta YOSHII
-
Publication number: 20160008333Abstract: The present invention relates to a prophylactic or therapeutic agent for a posterior ocular disease containing the compound represented by a formula (1), its enantiomer or diastereomer, or their pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: February 27, 2014Publication date: January 14, 2016Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Atsushi YOSHIDA, Sae AKAO, Shinji YONEDA, Komei OKABE, Tomomi KOHARA